The fallopian tube cancer therapeutics pipeline is a major focus for the pharmaceutical companies and researchers since it is one of the most debilitating women’s disease. The invention of novel drug delivery and the targeted therapy is expected to drive the pipeline growth for fallopian tube cancer. Increasing awareness regarding cancer treatment, advancement in technologies, high demand for safe and effective medications and high prevalence of cancer are driving the growth of fallopian tube cancer therapeutics pipeline.
The fallopian tube is a part of female reproductive system and are a pair of thin tubes that transport ova from women’s ovaries to the uterus where they are either fertilized by male sperm or discarded during menstruation. In fallopian tube cancer, an abnormal growth of malignant cells occurs in one or both of a woman's fallopian tubes. The most common fallopian tube cancers are papillary serous adenocarcinomas. The papillary serous adenocarcinomas are an abnormal growth of the fallopian tube cells. Fallopian tube cancer mainly affects women from ages 18-88, and is most commonly found in women aged between 40 and 65 years old.
The pipeline of fallopian tube cancer therapeutics includes, but is not limited to atezolizumab (MPDL 3280A), Ribociclib and Binimetinib. Atezolizumab is being developed by F. Hoffmann-La Roche AG. It is a monoclonal antibody targeting programmed cell death-1 ligand 1 (PD-L1 or CD274 antigen). PD-L1 plays an important role in suppressing the immune system triggered by disease.
Various pharma companies are entering in collaborations for research and development of fallopian tube cancer. In November 2015, Array BioPharma and Pierre Fabre, a French multinational pharmaceutical and cosmetics company, entered into a global development and commercialization collaboration for binimetinib and encorafenib. Under the terms of the agreement, Array will receive an upfront payment of $30 million and is entitled to receive up to $425 million if certain development and commercialization milestones are achieved. Array will also be eligible for robust, tiered double-digit royalties. Array retains exclusive commercialization rights for binimetinib and encorafenib in the U.S., Canada, Japan, South Korea and Israel. Pierre Fabre will have exclusive rights to commercialize both the products in rest of the world, including Europe, Asia and Latin America. Also, increasing awareness regarding the treatment has been driving the pipeline growth. However, high cost of treatment and various side effects associated with the treatment act as key barriers hindering the growth of the pipeline.
According to the National Cancer Institute, a part of National Institute of Health (NIH), in the year 2016, an estimated 22,280 women in the U.S. are expected be diagnosed with ovarian cancer, and the vast majority of these are high-grade serous ovarian cancers which begins in a fallopian tube. Around 14,240 deaths from the fallopian tube occurred in the year 2016.
Some of the companies having a pipeline of fallopian tube cancer therapeutics include Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline plc, Incyte Corporation and F. Hoffmann-La Roche AG.